Side-by-side comparison of AI visibility scores, market position, and capabilities
SF optical industry B2B platform unifying eyewear ordering, tracking, and billing for eye care professionals; YC W23 $3.82M Initialized Capital seed targeting $68.3B US optical market fragmented across doctors, labs, and insurers.
SpecCheck is a San Francisco-based optical industry B2B platform — backed by Y Combinator (W23) with $3.82 million raised including a $3.7 million seed round led by Initialized Capital in October 2023 — providing eye care professionals and optical businesses with a unified prescription eyewear ordering, tracking, and billing system that connects optometrists, opticians, and optical labs in a single workflow to eliminate the manual coordination, phone calls, and paper-based processes that dominate the $68.3 billion US optical industry. Founded in 2023, SpecCheck addresses the fragmentation in optical dispensing workflow where prescriptions travel between eye doctors, dispensing opticians, and fulfillment labs through a mix of fax, phone, and disconnected software systems.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.